Urinary liver-type fatty acid-binding protein and progression of diabetic nephropathy in type 1 diabetes

Diabetes Care

Volumn 36, Issue 7, 2013, Pages 2077-2083

  Panduru, Nicolae M ^a,b   Forsblom, Carol ^b,c   Saraheimo, Markku ^b,c   Thorn, Lena ^b,c   Bierhaus, Angelika ^d   Humpert, Per M ^e   Groop, Per Henrik ^b,c,f  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b FOLKHÄLSAN INSTITUTE OF GENETICS   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e Stoffwechselzentrum Rhein Pfalz   (Germany)

^f BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CHOLESTEROL; CREATININE; FATTY ACID BINDING PROTEIN; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; URINARY LIVER TYPE FATTY ACID BINDING PROTEIN;

ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; SYSTOLIC BLOOD PRESSURE; URINALYSIS;

ADULT; ALBUMINURIA; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; FATTY ACID-BINDING PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 84879595654     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-1868     Document Type: Article

References (33)

1. Groop PH, Thomas MC, Moran JL., et al.; FinnDiane Study Group. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 2009;58:1651-1658
2. Forsblom C, Harjutsalo V, Thorn LM., et al.; FinnDiane StudyGroup. Competingrisk analysis of ESRD and death among patients with type 1 diabetes and macroalbuminuria. J Am Soc Nephrol 2011;22: 537-544
3. VibertiGC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982;1:1430-1432
4. Fioretto P, Steffes MW, Mauer M. Glomerular structure in nonproteinuric IDDM patients with various levels of albuminuria. Diabetes 1994;43:1358-1364
5. Forsblom CM, Groop PH, Ekstrand A, Groop LC. Predictive value of microalbuminuria in patients with insulindependent diabetes of long duration. BMJ 1992;305:1051-1053
6. Molitch ME, Steffes M, Sun W., et al.; Epidemiology of Diabetes Interventions and Complications Study Group. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care 2010; 33:1536-1543
7. Magri CJ, Fava S. The role of tubular injury in diabetic nephropathy. Eur J Intern Med 2009;20:551-555
8. Kamijo A, Sugaya T, Hikawa A., et al. Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules. Am J Pathol 2004;165: 1243-1255
9. Kamijo A, Sugaya T, Hikawa A., et al. Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease. Mol Cell Biochem 2006; 284:175-182
10. Nielsen SE, Sugaya T, Tarnow L., et al. Tubular and glomerular injury in diabetes and the impact of ACE inhibition. Diabetes Care 2009;32:1684-1688
11. Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy. Diabetes Care 2005; 28:2728-2732
12. Nakamura T, Sugaya T, Koide H. Angiotensin II receptor antagonist reduces urinary liver-type fatty acid-binding protein levels in patients with diabetic nephropathy and chronic renal failure. Diabetologia 2007;50:490-492
13. FergusonMA, Vaidya VS,Waikar SS., et al. Urinary liver-type fatty acid-binding protein predicts adverse outcomes in acute kidney injury. Kidney Int 2010;77:708-714
14. Mou S,Wang Q, Li J, Shi B, Ni Z. Urinary excretion of liver-type fatty acid-binding protein as a marker of progressive kidney function deterioration in patients with chronic glomerulonephritis. Clin Chim Acta 2012;413:187-191
15. Nakamura T, Sugaya T, Ebihara I, Koide H. Urinary liver-type fatty acid-binding protein: discrimination between IgA nephropathy and thin basementmembrane nephropathy. Am J Nephrol 2005;25:447-450
16. Kamijo-Ikemori A, Sugaya T, Yasuda T., et al. Clinical significance of urinary livertype fatty acid-binding protein in diabetic nephropathy of type 2 diabetic patients. Diabetes Care 2011;34:691-696
17. Nielsen SE, Sugaya T, Hovind P, Baba T, Parving HH, Rossing P. Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients.DiabetesCare 2010;33:1320-1324
18. Thorn LM, Forsblom C, Fagerudd J., et al.; FinnDiane Study Group. Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care 2005;28:2019-2024
19. Thorn LM, Forsblom C, Wadén J., et al.; Finnish Diabetic Nephropathy (Finn- Diane) Study Group.Metabolic syndrome as a risk factor for cardiovascular disease, mortality, and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care 2009;32:950-952
20. Stevens LA, Coresh J, Schmid CH., et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 2008;51:395-406
21. Nakamura T, Sugaya T, Kawagoe Y., et al. Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease. Am J Med Sci 2007;333:321-326
22. Maatman RG, van de Westerlo EM, van Kuppevelt TH, Veerkamp JH. Molecular identification of the liver- and the hearttype fatty acid-binding proteins in human and rat kidney. Use of the reverse transcriptase polymerase chain reaction. Biochem J 1992;288:285-290
23. Costacou T, Ellis D, Fried L, Orchard TJ. Sequence of progression of albuminuria and decreased GFR in persons with type 1 diabetes: a cohort study. Am J Kidney Dis 2007;50:721-732
24. Kamijo A, Kimura K, Sugaya T., et al. Urinary free fatty acids bound to albumin aggravate tubulointerstitial damage. Kidney Int 2002;62:1628-1637
25. Yaqoob M, McClelland P, Patrick AW., et al. Evidence of oxidant injury and tubular damage in early diabetic nephropathy. QJM 1994;87:601-607
26. Liu F, Brezniceanu ML, Wei CC., et al. Overexpression of angiotensinogen increases tubular apoptosis in diabetes. J Am Soc Nephrol 2008;19:269-280
27. YaqoobM, PatrickAW,McClelland P., et al. Relationship between markers of endothelial dysfunction, oxidant injury and tubular damage in patients with insulin-dependent diabetes mellitus. Clin Sci (Lond) 1993;85: 557-562
28. Singh DK, Winocour P, Farrington K. Mechanisms of disease: the hypoxic tubular hypothesis of diabetic nephropathy. Nat Clin Pract Nephrol 2008;4:216-226
29. Yamamoto T, Noiri E, Ono Y., et al. Renal L-type fatty aciddbinding protein in acute ischemic injury. J Am Soc Nephrol 2007; 18:2894-2902
30. Thomas ME, Schreiner GF. Contribution of proteinuria to progressive renal injury: consequences of tubular uptake of fatty acid bearing albumin. Am J Nephrol 1993;13:385-398
31. SasakiH, Kamijo-Ikemori A, Sugaya T., et al. Urinary fatty acids and liver-type fatty acid binding protein in diabetic nephropathy. Nephron Clin Pract 2009;112:c148-c156
32. Al-Khoury S, Afzali B, Shah N, Covic A, Thomas S, Goldsmith DJ. Anaemia in diabetic patients with chronic kidney diseasedprevalence and predictors. Diabetologia 2006;49:1183-1189
33. von EynattenM, BaumannM,Heemann U., et al. Urinary L-FABP and anaemia: distinct roles of urinary markers in type 2 diabetes. Eur J Clin Invest 2010;40:95-102